Sun Pharma stock at INR 1,760.00, 14.0 percent below high on October 9, 2026

Published on 10/12/2026 at 13:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sun Pharma stock was last at INR 1,760.00 on October 9, 2026. It stood 14.00 percent below the INR 2,046.90 high, with a P/E of 34.91.

Key points in brief

Sun Pharma stock was last at INR 1,760.00 on October 9, 2026, 14.00 percent below its 52-week high.
The latest reported quarter was the first quarter of fiscal 2027, with revenue of INR 153.00 billion.
The stock carried a P/E ratio of 34.91 and market capitalization of INR 4.2 trillion.
Dr. Reddy's and Cipla provided peer valuation context, with P/E ratios of 30.96 and 31.45.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma stock (INE044A01036) was last at INR 1,760.00 on the National Stock Exchange on October 9, 2026, leaving the price 14.00 percent below its 52-week high of INR 2,046.90. The dated quote places the company in a valuation-led market report rather than a fresh price-move story.

Price remains below yearly high

The stock's 52-week low was INR 1,583.70, putting the latest close INR 176.30 above that level. The distance from the high is calculated from the same INR 1,760.00 price and INR 2,046.90 high, making the range more informative than a daily direction signal.

Trading volume was 1,141,641 shares against an average volume of 1,875,762 shares. The latest volume was therefore 39.15 percent below the average, while market capitalization stood at INR 4.2 trillion as of October 12, 2026.

First quarter supplies the earnings base

Sun Pharma reported first-quarter fiscal 2027 revenue of INR 153.00 billion, up 10.10 percent from the comparable period, according to Stockfin. The same period produced operating profit of INR 36.79 billion and net profit of INR 29.11 billion, with earnings per share of INR 12.10.

Sun's investor information page identifies the reporting period as quarter one of fiscal 2026-27, covering April through June, and lists the associated financial results and earnings materials. The comparison matters because revenue growth exceeded the stock's 10.00 percent threshold while the operating margin was 24.10 percent, according to Stockfin.

Comparison with peers

Sun Pharma (NSE, INR): , P/E 34.91, market capitalization INR 4.2 trillion
Dr. Reddy's (NSE, INR): plus 2.71 percent, P/E 30.96, market capitalization INR 1.0 trillion
Cipla (NSE, INR): plus 0.79 percent, P/E 31.45, market capitalization INR 1.1 trillion

Valuation stays central

Sun Pharma's P/E ratio was 34.91 and its trailing dividend yield was 0.01 percent as of October 12, 2026. Dr. Reddy's traded on a lower P/E of 30.96, while Cipla stood at 31.45, giving investors a direct valuation comparison across three Indian pharmaceutical companies.

The next dated corporate milestone is the postal-ballot result, which Sun Pharma said would be announced on or before November 3, 2026, in its October notice. The notice also set the voting period to close on October 31, 2026, so the calendar contains a defined governance event even as the stock remains below its yearly high.

Sun Pharma stock was last at INR 1,760.00 on October 9, 2026, on the NSE, compared with the 52-week high of INR 2,046.90 and the 52-week low of INR 1,583.70.